[Clinical heterogeneity and coexistence of diabetic neuropathies: difference and similarities between types 1 and 2 diabetes mellitus]
- PMID: 19942983
- DOI: 10.1590/s0004-27302009000700005
[Clinical heterogeneity and coexistence of diabetic neuropathies: difference and similarities between types 1 and 2 diabetes mellitus]
Abstract
Objective: To evaluate the heterogeneity and the coexistence of diabetic neuropathy (DNP) in type 1 (T1DM) and 2 (T2DM) diabetes mellitus.
Methods: 74 T2DM and 20 T1DM patients were evaluated according to age (years), time from diagnosis of diabetes (TDD, years), body mass index (BMI, kg/m(2)), HbA1c and DNP type (American Diabetes Association criteria).
Results: T1DM was younger (32.7 +/- 11.0 versus 56.9 +/- 10.3; p = 0.0001), leaner (BMI: 23.6 +/- 3.85 versus 28.4 +/- 5.3; p = 0.0005) and they had longer TDD (17.1 +/- 9.7 versus 10.4 +/- 6.8; p = 0.003). Cardiovascular autonomic neuropathy (CAN) (60% versus 32.4%; p = 0.02) and its coexistence with polyneuropathy (PN) (62.5% versus 33.3%; p = 0.03) were more common in T1DM. Chronic painful polyneuropathy (CPP) was more prevalent in T2DM (60.8% versus 30.0%; p = 0.009). Logistic regression showed HbA1c as an independent variable related to PN (p = 0.04) in both groups. TDD (p = 0.03) and CPP (p = 0.003) were related to CAN in T1DM. Age (p = 0.0004) was related to CPP in T2DM.
Conclusions: The DNP have shown a heterogeneity distribution in type 1 and type 2 diabetes mellitus. The related factors to different phenotypes of this complication, apart from hyperglycemia, may be variable between these two types of diabetes mellitus.
Similar articles
-
Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients.BMC Neurol. 2018 Aug 27;18(1):126. doi: 10.1186/s12883-018-1125-1. BMC Neurol. 2018. PMID: 30149797 Free PMC article.
-
High prevalence of diagnosed and undiagnosed polyneuropathy in subjects with and without diabetes participating in a nationwide educational initiative (PROTECT study).J Diabetes Complications. 2015 Nov-Dec;29(8):998-1002. doi: 10.1016/j.jdiacomp.2015.09.008. Epub 2015 Sep 14. J Diabetes Complications. 2015. PMID: 26482177
-
The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus.Curr Med Res Opin. 2018 Nov;34(11):2015-2022. doi: 10.1080/03007995.2018.1509304. Epub 2018 Sep 20. Curr Med Res Opin. 2018. PMID: 30084288
-
Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet.Diabetes Metab J. 2019 Feb;43(1):3-30. doi: 10.4093/dmj.2018.0259. Diabetes Metab J. 2019. PMID: 30793549 Free PMC article. Review.
-
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.J Diabetes Complications. 2017 Dec;31(12):1719-1727. doi: 10.1016/j.jdiacomp.2017.08.005. Epub 2017 Aug 12. J Diabetes Complications. 2017. PMID: 28939018 Review.
Cited by
-
Differences and Similarities in Neuropathy in Type 1 and 2 Diabetes: A Systematic Review.J Pers Med. 2021 Mar 22;11(3):230. doi: 10.3390/jpm11030230. J Pers Med. 2021. PMID: 33810048 Free PMC article. Review.
-
Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy.Cochrane Database Syst Rev. 2019 Jun 15;6(6):CD011265. doi: 10.1002/14651858.CD011265.pub2. Cochrane Database Syst Rev. 2019. PMID: 31201734 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical